Suma Krishnan Sells 25,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Suma Krishnan also recently made the following trade(s):

• On Friday, December 13th, Suma Krishnan sold 25,000 shares of Krystal Biotech stock. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $179.38 on Friday. The company has a 50 day moving average price of $163.50 and a 200-day moving average price of $174.07. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34. The company has a market capitalization of $5.17 billion, a PE ratio of 59.99 and a beta of 0.87.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech’s revenue was up 116.4% compared to the same quarter last year. During the same period last year, the company posted $0.30 earnings per share. On average, analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors have recently bought and sold shares of the business. US Bancorp DE increased its holdings in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after buying an additional 82 shares during the period. Summit Investment Advisors Inc. increased its holdings in Krystal Biotech by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock valued at $407,000 after buying an additional 82 shares during the period. Crossmark Global Holdings Inc. grew its holdings in Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock worth $362,000 after purchasing an additional 121 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock worth $1,822,000 after purchasing an additional 121 shares during the last quarter. Finally, Perigon Wealth Management LLC grew its holdings in Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock worth $1,200,000 after purchasing an additional 123 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KRYS has been the subject of several analyst reports. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective for the company. Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Friday, February 28th. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $220.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).